An Alto drug candidate for major depressive disorder failed to meet primary and secondary goals of a placebo-controlled Phase 2b test. The disappointing result could stymie plans for further tests of the small molecule in PTSD and bipolar depression.
Autobahn Therapeutics’ platform technology enables small molecules to selectively hit targets in the brain. In addition to a lead program ready for Phase 2 testing in two types of depression, the startup has a preclinical molecule with potential applications in neuroinflammatory disorders such as multiple sclerosis.
Neurologists and health care practitioners must evolve with the world. Telemedicine carts assist in this evolution by serving as an intermediary between patients and doctors.
Alkermes antipsychotic drug Lybalvi now has FDA approval. Though the field of neuropsychiatric drugs is crowded with generic medications, Alkermes believes Lybalvi, designed to mitigate the weight gain side effect common with mood disorder drugs, could have an advantage.
The company's shares fell more than 20 percent Monday on data from the trials of lumateperone, but an analyst wrote that the reason for the high placebo response rate that led to one trial's failure remains unclear.
Otsuka also made an $88 million investment as part of the expansion. The companies plan to launch Abilify MyCite, approved in November 2017, by the end of this year.
The consortium will use induced pluripotent stem cell (iPSC) technology — a type of stem cell that can be generated from adult stem cells — to find better treatments for the two psychiatric conditions.
At a time when AI is reshaping pharma, Reverba Global CEO Cheryl Lubbert explained in an interview why empathy, context, and ethics still require a human touch.
Tal Medical is using a neurostimulation treatment that could potentially change the face of psychiatric treatment entirely.
Demi Lovato is using her celebrity platform to share about the realities of her experience with bipolar disorder.
Imagine you break your leg. You pop an oxycodone, and the pain will quickly subside. Physical pain can usually be treated quickly – but the same does not hold true for mental health. For instance, it takes four to 10 weeks for your standard SSRI to kick in and start treating depression. That just isn’t fast enough for patients […]